Clinical Trial Update: Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 [NA]

View source ↗

Summary

A clinical trial update on oblimersen plus dacarbazine for advanced malignant melanoma that previously responded to treatment in the GENTA-GM301 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Genasense (oblimersen)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Melanoma (Skin) | NA | Status: UNKNOWN